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Abstract
The pathomechanism of primary polydipsia is poorly understood. Recent animal data 
reported a connection between fibroblast growth factor 21 (FGF-21) and elevated fluid 
intake independently of hormonal control by the hormone arginine-vasopressin (AVP) and 
osmotic stimulation. We therefore compared circulating FGF-21 levels in patients with primary 
polydipsia to patients with AVP deficiency (central diabetes insipidus) and healthy volunteers. 
In this prospective cohort study, we analyzed FGF-21 levels of 20 patients with primary 
polydipsia, 20 patients with central diabetes insipidus and 20 healthy volunteers before and 
after stimulation with hypertonic saline infusion targeting a plasma sodium level ≥150 mmol/L. 
The primary outcome was the difference in FGF-21 levels between the three groups. Baseline 
characteristics were similar between the groups except for patients with central diabetes 
insipidus being heavier. There was no difference in baseline FGF-21 levels between patients 
with primary polydipsia and healthy volunteers (122 pg/mL (52,277) vs 193 pg/mL (48,301), but 
higher levels in patients with central diabetes insipidus were observed (306 pg/mL (114,484); 
P = 0.037). However, this was not confirmed in a multivariate linear regression analysis after 
adjusting for age, sex, BMI and smoking status. Osmotic stimulation did not affect FGF-21 
levels in either group (difference to baseline: primary polydipsia −23 pg/mL (−43, 22); central 
diabetes insipidus 17 pg/mL (−76, 88); healthy volunteers −6 pg/mL (−68, 22); P = 0.45). To 
conclude, FGF-21 levels are not increased in patients with primary polydipsia as compared to 
central diabetes insipidus or healthy volunteers. FGF-21 therefore does not seem to be causal 
of elevated fluid intake in these patients.
Introduction
Polyuria polydipsia syndrome is a common problem in 
clinical practice with the two main entities being primary 
polydipsia and central diabetes insipidus (1). While the 
pathomechanism of central diabetes insipidus is well 
known (insufficient vasopressin (AVP) secretion from 
the pituitary (2, 3, 4)), the cause of primary polydipsia 
(with excessive fluid intake often without obvious cause) 
remains unclear.
Fibroblast growth factor 21 (FGF-21) is a peptide 
hormone synthesized by several organs (e.g. liver, 
brown adipose tissue, muscle, pancreas). It is involved 
in the regulation of energy homeostasis and triggered by 
metabolic stress (5, 6). Thus, the main focus on FGF-21 to 
date is due to its involvement in the metabolic syndrome. 
Recently, several studies indicated a correlation between 
FGF-21 levels in humans with age, BMI, fat mass and 
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insulin resistance (7, 8, 9) as well as smoking status 
(10, 11). As exogenous administration of FGF-21 induces 
weight loss, it is currently evaluated as a new treatment 
for obesity (12, 13, 14).
Recent animal studies highlighted a different field 
of FGF-21 research and proposed a connection between 
FGF-21 and elevated fluid intake (15, 16, 17). Thereby, 
mice with elevated FGF-21 levels had a strong preference 
for water instead of sweetened fluids or alcohol (16). 
Exogenous injection of FGF-21 led to increased water 
intake without recruitment of the common pathway 
AVP/renin-angiotensin system, meanwhile a high salt diet 
or water deprivation did not induce FGF-21 production 
(15). A similar study (17) confirmed those findings in 
mice, however indicating that the increased fluid intake 
was secondary to an elevated urine output. This suggests 
an FGF-21-triggered pathway in the regulation of fluid 
homeostasis, independent of the known AVP release upon 
osmotic stimulation.
Whether FGF-21 levels are increased in patients 
with primary polydipsia providing a possible new 
pathomechanism for this disorder has, to our knowledge, 
not yet been evaluated. The primary goal of this study 
was therefore to compare FGF-21 levels in patients 
with primary polydipsia as compared to patients with 
a complete lack of AVP (i.e. central diabetes insipidus) 
and to healthy volunteers. Secondly, we aimed to assess 
the effect of osmotic stimulation with hypertonic saline 
infusion upon FGF-21 levels.
Materials and methods
Study design and participants
Twenty patients with primary polydipsia and 20 patients 
with complete central diabetes insipidus from the 
prospective multicenter CODDI study (18) and 20 healthy 
volunteers from the prospective multicenter CoNORM 
study (19) undergoing an osmotic stimulation test with 
hypertonic (3%) saline infusion between 2013 and 2017 
were included. Patients were randomly selected, healthy 
volunteers were age and BMI matched to patients with 
primary polydipsia. Full details of the studies rationales, 
designs and statistical analyses have been published 
elsewhere (18, 19). Both studies were registered on 
ClinicalTrials.gov (NCT01940614 / NCT02647736). They 
were approved by the Ethical Committee Northwest and 
Central Switzerland, University of Basel, Basel, Switzerland 
and the Ethical Committee of the University of Würzburg, 
Würzburg, Germany. Consent has been obtained from 
each patient or participant after full explanation of the 
purpose and nature of all procedures used.
Eligible patients were aged 18 years or older and had 
confirmed primary polydipsia or complete central diabetes 
insipidus. Patients with glucosuric polyuria, electrolyte 
disorders, untreated or insufficiently replaced pituitary-, 
adrenal- or thyroid deficiency, impaired kidney function, 
heart failure, uncontrolled hypertension or a history of 
epilepsy were ineligible.
Healthy volunteers were aged 18 years or older and 
normonatremic. Exclusion criteria included a history or 
presence of polyuria-polydipsia syndrome, any chronic or 
therapy-requiring diseases, chronic alcohol consumption 
or drug intake (except oral contraception).
Pregnancy or breastfeeding was an exclusion criterion 
in both studies.
Test protocol
No food intake was allowed after midnight, no fluid 
intake after 6:00 h on the test day. Diuretic or antidiuretic 
medications were discontinued for at least 24 h, smoking 
and alcohol were prohibited for at least 12 h before the 
test. Participants then underwent the hypertonic saline 
infusion test between 8:00 h and 11:00 h. After an initial 
250 mL bolus, infusion of 3% saline was administered at 
an infusion rate of 0.15 mL per kg bodyweight per minute. 
Sodium levels were controlled every 30 min with venous 
blood gas analysis. Blood samples for the measurement 
of plasma osmolality, sodium, copeptin (CT-proAVP – a 
stable and reliable surrogate marker for AVP (1)) and 
FGF-21 were obtained at baseline and as soon as sodium 
levels reached ≥150 mmol/L.
Laboratory measurements
Blood samples for plasma osmolality and sodium were 
processed as routine laboratory measurements. Blood 
samples for copeptin and FGF-21 analysis were taken 
into EDTA tubes, immediately centrifuged at 4°C and 
stored at −80°C until central batch analysis. Plasma 
copeptin was then measured by a commercial automated 
immunofluorescence assay (B.R.A.H.M.S KRYPTOR 
Copeptin proAVP, Thermo Scientific Biomarkers). FGF-21 
analysis was performed on the Simple Plex Ella microfluidic 
platform (Protein Simple, CA, USA) using detection 
antibodies based on the human FGF-21 quantikine ELISA 
(R&D systems). The coefficients of variation for the 
FGF-21 assay were reported as follows: intra-assay 
CV 8.2%, inter-assay CV 7.8%.
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Statistical analysis
The full analysis set included 60 subjects who completed 
the whole procedure. Results are shown as median and 
interquartile range (IQR) and number and percentage 
(%) unless stated otherwise. The Mann–Whitney U test 
was applied for two group comparisons of continuous 
variables. The Kruskal–Wallis test was applied for three 
group comparisons of continuous data. Correlation 
between baseline and stimulated FGF-21 with patients’ 
characteristics and laboratory values were computed using 
the Spearman’s Rank Correlation coefficient. Univariate 
linear regression models were used to assess the influence 
of diagnosis, age, BMI, sex and smoking status on 
FGF-21 levels. To adjust for these as confounding factors, 
a multiple linear regression model was performed.
Statistical analyses were performed using the statistic 
programs GraphPad PRISM version 7.03 and R statistical 
Software (MathSoft, Seattle, WA, USA). All hypothesis 
testing were two-tailed and P values <0.05 were considered 
statistically significant.
Results
Baseline characteristics are shown in Table 1.
As the groups were age and BMI matched, there was 
no statistical difference between baseline characteristics in 
patients with polydipsia and healthy volunteers (primary 
polydipsia: median age 31.5 years (IQR 23.3, 47.3), BMI 
24.5 kg/m2 (IQR 22.5, 26.1); vs healthy volunteers: age 
30  years (IQR 23.3, 43.8), BMI 24.7 kg/m2 (IQR 22.5, 
26.1)), but patients with central diabetes insipidus were 
slightly older and had a higher BMI (median age 43.5 years 
(IQR 28.5, 49), BMI 29.0 kg/m2 (IQR 23.2, 30.9)). Around 
two-thirds were female participants (primary polydipsia 
65%, central diabetes insipidus 75%, healthy volunteers 
60%), the percentage of smokers was similar between the 
three groups (primary polydipsia 25%, central diabetes 
insipidus 20%, healthy volunteers 20%).
At baseline and after osmotic stimulation, plasma 
sodium and osmolality were significantly higher in 
patients with central diabetes insipidus compared to 
patients with primary polydipsia and healthy volunteers 
(Table  1). Copeptin levels were low in patients with 
central diabetes insipidus with no change upon osmotic 
stimulation, while they increased significantly in the 
other two groups (Fig. 1A and Table 1).
There was a statistically significant difference in 
baseline FGF-21 levels between all three groups, indicating Ta
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higher baseline FGF-21 levels in patients with central 
diabetes insipidus (primary polydipsia 122 pg/mL (IQR 
52, 277), central diabetes insipidus 306 pg/mL (IQR 114, 
484) and healthy volunteers 193 pg/mL (IQR 48, 301); 
P value 0.037). However, this effect was not confirmed 
after adjusting for age, sex, BMI and smoking status in a 
multivariate linear regression analysis (Table 2).
Osmotic stimulation did not affect FGF-21 levels in 
either group (difference to baseline: primary polydipsia 
−23 pg/mL (IQR −43, 22); central diabetes insipidus 
17 pg/mL (IQR −76, 88); healthy volunteers −6 pg/mL 
(−68, 22); P = 0.45) (Figs  1B and 2). No correlation was 
found for baseline or stimulated FGF-21 levels with 
plasma sodium, -osmolality, -copeptin levels nor age, BMI 
or amount of daily fluid intake (data not shown).
Discussion
We here show for the first time the course of FGF-
21 levels in patients with primary polydipsia, central 
diabetes insipidus and healthy volunteers before and 
after osmotic stimulation. Our main finding is that there 
is no difference in FGF-21 levels between patients with 
excessive fluid intake and hypotonic polyuria possessing 
different functionality of antidiuretic AVP activity and 
between healthy volunteers.
Despite being a common disorder, the 
pathomechanism of primary polydipsia is still poorly 
understood. An association between mental disorders 
and polydipsia has been described (20, 21, 22), but a 
recent evaluation of 82 patients with primary polydipsia 
revealed a prevalence of mental diseases in only 27% (18). 
Although baseline copeptin – the stable surrogate marker 
for AVP (1) – is often osmotically suppressed in patients 
with primary polydipsia, the osmotic sensitivity of AVP-
dependent antidiuresis is preserved in these patients as 
shown here and in previous studies (18, 23). Thus, the 
osmotically sensitive AVP system is functionally intact 
and alternative mechanisms must be responsible for 
the development of primary polydipsia. One interesting 
candidate to be addressed is the FGF-21 system. As shown 
in animal studies, elevated FGF-21 levels and exogenous 
FGF-21 application result in elevated water intake and 
diuresis respectively (15, 16, 17). Interestingly, in our 
study, we found no difference in FGF-21 levels between 
patients with primary polydipsia and central diabetes 
Figure 1
(A) Copeptin levels before and after osmotic 
stimulation with hypertonic saline infusion.  
(B) FGF-21 levels before and after osmotic 
stimulation with hypertonic saline infusion. 
Values shown as box plots with the middle line 
representing the median, the boxes the 25th to 
the 75th percentile and the whiskers 1.5 of the 
interquartile range, dots representing outliers.
Table 2 Univariate and multiple linear regression analysis for 
baseline FGF-21 levels.
 
 
Univariate linear 
regression analysis
Multivariate linear 
regression analysis
Estimate (95% CI) P value Estimate (95% CI) P value
Central DIa 521 (−17 to 1060) 0.063 371 (−173 to 915) 0.19
Healthya 12 (−526 to 550) 0.069 61 (−173 to 915) 0.81
Age 16 (−3 to 36) 0.118 2 (−19 to 23) 0.86
Sex: male −114 (−594 to 366) 0.643 −119 (−573 to 333) 0.61
BMI 65 (5–124) 0.036 56 (−10 to 123) 0.11
Smoking yes 684 (163–1206) 0.013 760 (246–1274) 0.005
aReference to primary polydipsia. Statistically significant variables are 
highlighted in bold.
BMI, body mass index; DI, diabetes insipidus; FGF-21, fibroblast growth 
factor 21; Healthy, healthy volunteers.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0469
https://ec.bioscientifica.com © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 11/21/2019 11:38:59AM
via free access
J Refardt et al. FGF21 in polydipsia 15057:12
insipidus nor healthy volunteers. FGF-21 therefore seems 
not to be causal of elevated fluid intake in patients with 
primary polydipsia.
In agreement to the published animal data (15), 
osmotic stimulation did not lead to an increase in FGF-
21 levels in any of the studied groups. There was also 
no correlation with either plasma sodium, –osmolality 
or –copeptin levels. In case of FGF-21 playing a role in 
fluid homeostasis, it seems to be working independently 
of osmotic control. To further investigate this question, it 
would be of interest to evaluate the impact of exogenous 
FGF-21 on fluid intake in humans. Unfortunately, this 
information is missing in published data (24, 25, 26).
In line with previous findings (5, 8, 9, 10), FGF-21 
levels in our study were influenced by BMI and smoking 
habits but independent of sex. Age did not affect the 
results, but this could be due to the small age differences 
in our cohort.
The following limitations have to be mentioned. First, 
this was an exploratory study including 60 participants 
from three different groups which increased the variance 
in results. However, as patients were carefully selected 
and had confirmed central diabetes insipidus or primary 
polydipsia, the results should be very representative. 
Second, patients with central diabetes insipidus were 
slightly heavier and older compared to patients with 
primary polydipsia and healthy volunteers. We tried to 
adjust for this bias by multiple linear regression analysis.
In conclusion, we here show that FGF-21 levels are 
not higher in patients with primary polydipsia than in 
patients with central diabetes insipidus or than in healthy 
volunteers. Therefore, it is unlikely that FGF-21 is the 
cause of elevated fluid intake in patients with primary 
polydipsia. Clinical studies in humans with exogenous 
FGF-21 are needed to further investigate its possible role as 
an AVP-independent stimulator of polyuria and polydipsia.
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